These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

2890 related items for PubMed ID: 25787767

  • 1. Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAF(V600E) melanoma.
    Hu-Lieskovan S, Mok S, Homet Moreno B, Tsoi J, Robert L, Goedert L, Pinheiro EM, Koya RC, Graeber TG, Comin-Anduix B, Ribas A.
    Sci Transl Med; 2015 Mar 18; 7(279):279ra41. PubMed ID: 25787767
    [Abstract] [Full Text] [Related]

  • 2. The BRAF and MEK Inhibitors Dabrafenib and Trametinib: Effects on Immune Function and in Combination with Immunomodulatory Antibodies Targeting PD-1, PD-L1, and CTLA-4.
    Liu L, Mayes PA, Eastman S, Shi H, Yadavilli S, Zhang T, Yang J, Seestaller-Wehr L, Zhang SY, Hopson C, Tsvetkov L, Jing J, Zhang S, Smothers J, Hoos A.
    Clin Cancer Res; 2015 Apr 01; 21(7):1639-51. PubMed ID: 25589619
    [Abstract] [Full Text] [Related]

  • 3. Controversies in the management of advanced melanoma: "gray" areas amid the "black and blue".
    Jarkowski A, Norris L, Trinh VA.
    Ann Pharmacother; 2014 Nov 01; 48(11):1456-68. PubMed ID: 25056920
    [Abstract] [Full Text] [Related]

  • 4. Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial.
    Grob JJ, Amonkar MM, Karaszewska B, Schachter J, Dummer R, Mackiewicz A, Stroyakovskiy D, Drucis K, Grange F, Chiarion-Sileni V, Rutkowski P, Lichinitser M, Levchenko E, Wolter P, Hauschild A, Long GV, Nathan P, Ribas A, Flaherty K, Sun P, Legos JJ, McDowell DO, Mookerjee B, Schadendorf D, Robert C.
    Lancet Oncol; 2015 Oct 01; 16(13):1389-98. PubMed ID: 26433819
    [Abstract] [Full Text] [Related]

  • 5. Clinicopathologic features associated with efficacy and long-term survival in metastatic melanoma patients treated with BRAF or combined BRAF and MEK inhibitors.
    Menzies AM, Wilmott JS, Drummond M, Lo S, Lyle M, Chan MM, Thompson JF, Guminski A, Carlino MS, Scolyer RA, Kefford RF, Long GV.
    Cancer; 2015 Nov 01; 121(21):3826-35. PubMed ID: 26218930
    [Abstract] [Full Text] [Related]

  • 6. Targeted Therapy Given after Anti-PD-1 Leads to Prolonged Responses in Mouse Melanoma Models through Sustained Antitumor Immunity.
    Phadke MS, Chen Z, Li J, Mohamed E, Davies MA, Smalley I, Duckett DR, Palve V, Czerniecki BJ, Forsyth PA, Noyes D, Adeegbe DO, Eroglu Z, Nguyen KT, Tsai KY, Rix U, Burd CE, Chen YA, Rodriguez PC, Smalley KSM.
    Cancer Immunol Res; 2021 May 01; 9(5):554-567. PubMed ID: 33653716
    [Abstract] [Full Text] [Related]

  • 7. Improved overall survival in melanoma with combined dabrafenib and trametinib.
    Robert C, Karaszewska B, Schachter J, Rutkowski P, Mackiewicz A, Stroiakovski D, Lichinitser M, Dummer R, Grange F, Mortier L, Chiarion-Sileni V, Drucis K, Krajsova I, Hauschild A, Lorigan P, Wolter P, Long GV, Flaherty K, Nathan P, Ribas A, Martin AM, Sun P, Crist W, Legos J, Rubin SD, Little SM, Schadendorf D.
    N Engl J Med; 2015 Jan 01; 372(1):30-9. PubMed ID: 25399551
    [Abstract] [Full Text] [Related]

  • 8. Clinical, Molecular, and Immune Analysis of Dabrafenib-Trametinib Combination Treatment for BRAF Inhibitor-Refractory Metastatic Melanoma: A Phase 2 Clinical Trial.
    Chen G, McQuade JL, Panka DJ, Hudgens CW, Amin-Mansour A, Mu XJ, Bahl S, Jané-Valbuena J, Wani KM, Reuben A, Creasy CA, Jiang H, Cooper ZA, Roszik J, Bassett RL, Joon AY, Simpson LM, Mouton RD, Glitza IC, Patel SP, Hwu WJ, Amaria RN, Diab A, Hwu P, Lazar AJ, Wargo JA, Garraway LA, Tetzlaff MT, Sullivan RJ, Kim KB, Davies MA.
    JAMA Oncol; 2016 Aug 01; 2(8):1056-64. PubMed ID: 27124486
    [Abstract] [Full Text] [Related]

  • 9. Dabrafenib and trametinib, alone and in combination for BRAF-mutant metastatic melanoma.
    Menzies AM, Long GV.
    Clin Cancer Res; 2014 Apr 15; 20(8):2035-43. PubMed ID: 24583796
    [Abstract] [Full Text] [Related]

  • 10. Combined BRAF and MEK inhibition with PD-1 blockade immunotherapy in BRAF-mutant melanoma.
    Ribas A, Lawrence D, Atkinson V, Agarwal S, Miller WH, Carlino MS, Fisher R, Long GV, Hodi FS, Tsoi J, Grasso CS, Mookerjee B, Zhao Q, Ghori R, Moreno BH, Ibrahim N, Hamid O.
    Nat Med; 2019 Jun 15; 25(6):936-940. PubMed ID: 31171879
    [Abstract] [Full Text] [Related]

  • 11. Combination of dabrafenib plus trametinib for BRAF and MEK inhibitor pretreated patients with advanced BRAFV600-mutant melanoma: an open-label, single arm, dual-centre, phase 2 clinical trial.
    Schreuer M, Jansen Y, Planken S, Chevolet I, Seremet T, Kruse V, Neyns B.
    Lancet Oncol; 2017 Apr 15; 18(4):464-472. PubMed ID: 28268064
    [Abstract] [Full Text] [Related]

  • 12. BRAF and MEK inhibition variably affect GD2-specific chimeric antigen receptor (CAR) T-cell function in vitro.
    Gargett T, Fraser CK, Dotti G, Yvon ES, Brown MP.
    J Immunother; 2015 Jan 15; 38(1):12-23. PubMed ID: 25415284
    [Abstract] [Full Text] [Related]

  • 13. Cutaneous Toxic Effects of BRAF Inhibitors Alone and in Combination With MEK Inhibitors for Metastatic Melanoma.
    Carlos G, Anforth R, Clements A, Menzies AM, Carlino MS, Chou S, Fernandez-Peñas P.
    JAMA Dermatol; 2015 Oct 15; 151(10):1103-9. PubMed ID: 26200476
    [Abstract] [Full Text] [Related]

  • 14. Clinical and radiological response of BRAF inhibition and MEK inhibition in patients with brain metastases from BRAF-mutated melanoma.
    Geukes Foppen MH, Boogerd W, Blank CU, van Thienen JV, Haanen JB, Brandsma D.
    Melanoma Res; 2018 Apr 15; 28(2):126-133. PubMed ID: 29356790
    [Abstract] [Full Text] [Related]

  • 15. Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma.
    Robert C, Grob JJ, Stroyakovskiy D, Karaszewska B, Hauschild A, Levchenko E, Chiarion Sileni V, Schachter J, Garbe C, Bondarenko I, Gogas H, Mandalá M, Haanen JBAG, Lebbé C, Mackiewicz A, Rutkowski P, Nathan PD, Ribas A, Davies MA, Flaherty KT, Burgess P, Tan M, Gasal E, Voi M, Schadendorf D, Long GV.
    N Engl J Med; 2019 Aug 15; 381(7):626-636. PubMed ID: 31166680
    [Abstract] [Full Text] [Related]

  • 16. Future of combination therapy with dabrafenib and trametinib in metastatic melanoma.
    Zia Y, Chen L, Daud A.
    Expert Opin Pharmacother; 2015 Aug 15; 16(14):2257-63. PubMed ID: 26331795
    [Abstract] [Full Text] [Related]

  • 17. Combination Treatment of Patients with BRAF-Mutant Melanoma: A New Standard of Care.
    Simeone E, Grimaldi AM, Festino L, Vanella V, Palla M, Ascierto PA.
    BioDrugs; 2017 Feb 15; 31(1):51-61. PubMed ID: 28058658
    [Abstract] [Full Text] [Related]

  • 18. BRAF inhibition for advanced locoregional BRAF V600E mutant melanoma: a potential neoadjuvant strategy.
    Sloot S, Zager JS, Kudchadkar RR, Messina JL, Benedict JJ, Gonzalez RJ, DeConti R, Turner LM, McCardle T, Smalley KS, Weber JS, Sondak VK, Gibney GT.
    Melanoma Res; 2016 Feb 15; 26(1):83-7. PubMed ID: 26731560
    [Abstract] [Full Text] [Related]

  • 19. Dabrafenib, trametinib and pembrolizumab or placebo in BRAF-mutant melanoma.
    Ascierto PA, Ferrucci PF, Fisher R, Del Vecchio M, Atkinson V, Schmidt H, Schachter J, Queirolo P, Long GV, Di Giacomo AM, Svane IM, Lotem M, Bar-Sela G, Couture F, Mookerjee B, Ghori R, Ibrahim N, Moreno BH, Ribas A.
    Nat Med; 2019 Jun 15; 25(6):941-946. PubMed ID: 31171878
    [Abstract] [Full Text] [Related]

  • 20. Fatal gastrointestinal toxicity with ipilimumab after BRAF/MEK inhibitor combination in a melanoma patient achieving pathological complete response.
    Gonzalez-Cao M, Boada A, Teixidó C, Fernandez-Figueras MT, Mayo C, Tresserra F, Bustamante J, Viteri S, Puertas E, Santarpia M, Riso A, Barron F, Karachaliou N, Rosell R.
    Oncotarget; 2016 Aug 30; 7(35):56619-56627. PubMed ID: 27447748
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 145.